nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbamazepine—UGT2B7—Mycophenolic acid—systemic scleroderma	0.186	0.261	CbGbCtD
Carbamazepine—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.104	0.146	CbGbCtD
Carbamazepine—CYP2C8—Mometasone—systemic scleroderma	0.0661	0.0928	CbGbCtD
Carbamazepine—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0546	0.0767	CbGbCtD
Carbamazepine—CYP1A2—Pentoxifylline—systemic scleroderma	0.0346	0.0485	CbGbCtD
Carbamazepine—CYP1A2—Leflunomide—systemic scleroderma	0.033	0.0463	CbGbCtD
Carbamazepine—ABCB1—Lisinopril—systemic scleroderma	0.0302	0.0424	CbGbCtD
Carbamazepine—CYP2C9—Leflunomide—systemic scleroderma	0.0297	0.0417	CbGbCtD
Carbamazepine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0274	0.0384	CbGbCtD
Carbamazepine—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0263	0.0369	CbGbCtD
Carbamazepine—ABCB1—Captopril—systemic scleroderma	0.0226	0.0318	CbGbCtD
Carbamazepine—ABCC2—Methotrexate—systemic scleroderma	0.0219	0.0308	CbGbCtD
Carbamazepine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0178	0.025	CbGbCtD
Carbamazepine—CYP2C19—Prednisone—systemic scleroderma	0.0176	0.0248	CbGbCtD
Carbamazepine—ABCB1—Prednisone—systemic scleroderma	0.0142	0.02	CbGbCtD
Carbamazepine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0107	0.015	CbGbCtD
Carbamazepine—CYP3A4—Prednisone—systemic scleroderma	0.00853	0.012	CbGbCtD
Carbamazepine—ABCB1—Methotrexate—systemic scleroderma	0.00714	0.01	CbGbCtD
Carbamazepine—CYP2C9—cardial valve—systemic scleroderma	0.00609	0.371	CbGeAlD
Carbamazepine—RALBP1—smooth muscle tissue—systemic scleroderma	0.000934	0.057	CbGeAlD
Carbamazepine—UGT2B7—digestive system—systemic scleroderma	0.000738	0.045	CbGeAlD
Carbamazepine—RALBP1—digestive system—systemic scleroderma	0.000738	0.045	CbGeAlD
Carbamazepine—SCN9A—tendon—systemic scleroderma	0.000726	0.0442	CbGeAlD
Carbamazepine—RALBP1—tendon—systemic scleroderma	0.000702	0.0428	CbGeAlD
Carbamazepine—SCN4A—tendon—systemic scleroderma	0.000647	0.0395	CbGeAlD
Carbamazepine—SCN9A—lung—systemic scleroderma	0.000637	0.0388	CbGeAlD
Carbamazepine—RALBP1—lung—systemic scleroderma	0.000616	0.0376	CbGeAlD
Carbamazepine—SCN5A—digestive system—systemic scleroderma	0.000528	0.0322	CbGeAlD
Carbamazepine—ABCC2—digestive system—systemic scleroderma	0.000396	0.0241	CbGeAlD
Carbamazepine—ABCB1—blood vessel—systemic scleroderma	0.000384	0.0234	CbGeAlD
Carbamazepine—ABCC2—tendon—systemic scleroderma	0.000377	0.023	CbGeAlD
Carbamazepine—CYP2C19—digestive system—systemic scleroderma	0.00034	0.0207	CbGeAlD
Carbamazepine—CYP2B6—skin of body—systemic scleroderma	0.000333	0.0203	CbGeAlD
Carbamazepine—CYP1A2—digestive system—systemic scleroderma	0.000278	0.0169	CbGeAlD
Carbamazepine—CYP3A5—digestive system—systemic scleroderma	0.000268	0.0163	CbGeAlD
Carbamazepine—CYP2B6—digestive system—systemic scleroderma	0.000266	0.0162	CbGeAlD
Carbamazepine—CYP2C9—digestive system—systemic scleroderma	0.000264	0.0161	CbGeAlD
Carbamazepine—CYP1A2—lung—systemic scleroderma	0.000232	0.0141	CbGeAlD
Carbamazepine—CYP3A5—lung—systemic scleroderma	0.000224	0.0136	CbGeAlD
Carbamazepine—CYP2B6—lung—systemic scleroderma	0.000222	0.0136	CbGeAlD
Carbamazepine—CYP3A4—digestive system—systemic scleroderma	0.000201	0.0123	CbGeAlD
Carbamazepine—ABCB1—digestive system—systemic scleroderma	0.000142	0.00868	CbGeAlD
Carbamazepine—Dizziness—Captopril—systemic scleroderma	0.000132	0.000486	CcSEcCtD
Carbamazepine—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000132	0.000485	CcSEcCtD
Carbamazepine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000484	CcSEcCtD
Carbamazepine—Depression—Prednisone—systemic scleroderma	0.000131	0.000483	CcSEcCtD
Carbamazepine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000483	CcSEcCtD
Carbamazepine—Urticaria—Leflunomide—systemic scleroderma	0.000131	0.000481	CcSEcCtD
Carbamazepine—Body temperature increased—Leflunomide—systemic scleroderma	0.00013	0.000479	CcSEcCtD
Carbamazepine—Abdominal pain—Leflunomide—systemic scleroderma	0.00013	0.000479	CcSEcCtD
Carbamazepine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000129	0.000476	CcSEcCtD
Carbamazepine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000476	CcSEcCtD
Carbamazepine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000476	CcSEcCtD
Carbamazepine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000476	CcSEcCtD
Carbamazepine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000129	0.000475	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000129	0.000474	CcSEcCtD
Carbamazepine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000474	CcSEcCtD
Carbamazepine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000128	0.000473	CcSEcCtD
Carbamazepine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000128	0.000473	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000128	0.000473	CcSEcCtD
Carbamazepine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000473	CcSEcCtD
Carbamazepine—Insomnia—Lisinopril—systemic scleroderma	0.000128	0.000471	CcSEcCtD
Carbamazepine—Paraesthesia—Lisinopril—systemic scleroderma	0.000127	0.000468	CcSEcCtD
Carbamazepine—Vomiting—Captopril—systemic scleroderma	0.000127	0.000467	CcSEcCtD
Carbamazepine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000465	CcSEcCtD
Carbamazepine—Dyspnoea—Lisinopril—systemic scleroderma	0.000126	0.000464	CcSEcCtD
Carbamazepine—Rash—Captopril—systemic scleroderma	0.000126	0.000464	CcSEcCtD
Carbamazepine—Dermatitis—Captopril—systemic scleroderma	0.000126	0.000463	CcSEcCtD
Carbamazepine—Somnolence—Lisinopril—systemic scleroderma	0.000126	0.000463	CcSEcCtD
Carbamazepine—Headache—Captopril—systemic scleroderma	0.000125	0.000461	CcSEcCtD
Carbamazepine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00046	CcSEcCtD
Carbamazepine—Dyspepsia—Lisinopril—systemic scleroderma	0.000124	0.000458	CcSEcCtD
Carbamazepine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000124	0.000457	CcSEcCtD
Carbamazepine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000124	0.000457	CcSEcCtD
Carbamazepine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000456	CcSEcCtD
Carbamazepine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000456	CcSEcCtD
Carbamazepine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000453	CcSEcCtD
Carbamazepine—Decreased appetite—Lisinopril—systemic scleroderma	0.000123	0.000453	CcSEcCtD
Carbamazepine—Eosinophilia—Methotrexate—systemic scleroderma	0.000122	0.00045	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000122	0.000449	CcSEcCtD
Carbamazepine—Fatigue—Lisinopril—systemic scleroderma	0.000122	0.000449	CcSEcCtD
Carbamazepine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000449	CcSEcCtD
Carbamazepine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000447	CcSEcCtD
Carbamazepine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000447	CcSEcCtD
Carbamazepine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000121	0.000446	CcSEcCtD
Carbamazepine—Pancreatitis—Methotrexate—systemic scleroderma	0.000121	0.000446	CcSEcCtD
Carbamazepine—Constipation—Lisinopril—systemic scleroderma	0.000121	0.000445	CcSEcCtD
Carbamazepine—Pain—Lisinopril—systemic scleroderma	0.000121	0.000445	CcSEcCtD
Carbamazepine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000445	CcSEcCtD
Carbamazepine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000443	CcSEcCtD
Carbamazepine—Bradycardia—Prednisone—systemic scleroderma	0.00012	0.000443	CcSEcCtD
Carbamazepine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000441	CcSEcCtD
Carbamazepine—Diarrhoea—Azathioprine—systemic scleroderma	0.000119	0.000439	CcSEcCtD
Carbamazepine—ABCB1—lung—systemic scleroderma	0.000119	0.00725	CbGeAlD
Carbamazepine—Nausea—Captopril—systemic scleroderma	0.000118	0.000437	CcSEcCtD
Carbamazepine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000118	0.000436	CcSEcCtD
Carbamazepine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000435	CcSEcCtD
Carbamazepine—Asthenia—Leflunomide—systemic scleroderma	0.000118	0.000435	CcSEcCtD
Carbamazepine—Hallucination—Prednisone—systemic scleroderma	0.000117	0.000433	CcSEcCtD
Carbamazepine—Pancytopenia—Methotrexate—systemic scleroderma	0.000117	0.000432	CcSEcCtD
Carbamazepine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000116	0.000429	CcSEcCtD
Carbamazepine—Pruritus—Leflunomide—systemic scleroderma	0.000116	0.000429	CcSEcCtD
Carbamazepine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000116	0.000428	CcSEcCtD
Carbamazepine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000426	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000116	0.000426	CcSEcCtD
Carbamazepine—Dizziness—Azathioprine—systemic scleroderma	0.000115	0.000424	CcSEcCtD
Carbamazepine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000114	0.000419	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000416	CcSEcCtD
Carbamazepine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000113	0.000415	CcSEcCtD
Carbamazepine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000113	0.000415	CcSEcCtD
Carbamazepine—Diarrhoea—Leflunomide—systemic scleroderma	0.000112	0.000415	CcSEcCtD
Carbamazepine—Urticaria—Lisinopril—systemic scleroderma	0.000112	0.000414	CcSEcCtD
Carbamazepine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000413	CcSEcCtD
Carbamazepine—Abdominal pain—Lisinopril—systemic scleroderma	0.000112	0.000412	CcSEcCtD
Carbamazepine—Body temperature increased—Lisinopril—systemic scleroderma	0.000112	0.000412	CcSEcCtD
Carbamazepine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000111	0.00041	CcSEcCtD
Carbamazepine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000111	0.000409	CcSEcCtD
Carbamazepine—Vomiting—Azathioprine—systemic scleroderma	0.000111	0.000408	CcSEcCtD
Carbamazepine—Pneumonia—Methotrexate—systemic scleroderma	0.000111	0.000408	CcSEcCtD
Carbamazepine—Eye disorder—Prednisone—systemic scleroderma	0.00011	0.000407	CcSEcCtD
Carbamazepine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000407	CcSEcCtD
Carbamazepine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000406	CcSEcCtD
Carbamazepine—Infestation NOS—Methotrexate—systemic scleroderma	0.00011	0.000405	CcSEcCtD
Carbamazepine—Infestation—Methotrexate—systemic scleroderma	0.00011	0.000405	CcSEcCtD
Carbamazepine—Drowsiness—Methotrexate—systemic scleroderma	0.00011	0.000405	CcSEcCtD
Carbamazepine—Rash—Azathioprine—systemic scleroderma	0.00011	0.000405	CcSEcCtD
Carbamazepine—Dermatitis—Azathioprine—systemic scleroderma	0.00011	0.000404	CcSEcCtD
Carbamazepine—Depression—Methotrexate—systemic scleroderma	0.00011	0.000404	CcSEcCtD
Carbamazepine—Flushing—Prednisone—systemic scleroderma	0.00011	0.000404	CcSEcCtD
Carbamazepine—Headache—Azathioprine—systemic scleroderma	0.000109	0.000402	CcSEcCtD
Carbamazepine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000109	0.000402	CcSEcCtD
Carbamazepine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000402	CcSEcCtD
Carbamazepine—Dizziness—Leflunomide—systemic scleroderma	0.000109	0.000401	CcSEcCtD
Carbamazepine—Renal failure—Methotrexate—systemic scleroderma	0.000108	0.000398	CcSEcCtD
Carbamazepine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000397	CcSEcCtD
Carbamazepine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000107	0.000396	CcSEcCtD
Carbamazepine—Stomatitis—Methotrexate—systemic scleroderma	0.000107	0.000395	CcSEcCtD
Carbamazepine—Angiopathy—Prednisone—systemic scleroderma	0.000107	0.000395	CcSEcCtD
Carbamazepine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000107	0.000394	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000394	CcSEcCtD
Carbamazepine—Immune system disorder—Prednisone—systemic scleroderma	0.000107	0.000393	CcSEcCtD
Carbamazepine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000106	0.00039	CcSEcCtD
Carbamazepine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000106	0.00039	CcSEcCtD
Carbamazepine—Arrhythmia—Prednisone—systemic scleroderma	0.000105	0.000389	CcSEcCtD
Carbamazepine—Haematuria—Methotrexate—systemic scleroderma	0.000105	0.000386	CcSEcCtD
Carbamazepine—Vomiting—Leflunomide—systemic scleroderma	0.000105	0.000385	CcSEcCtD
Carbamazepine—Alopecia—Prednisone—systemic scleroderma	0.000104	0.000385	CcSEcCtD
Carbamazepine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000104	0.000384	CcSEcCtD
Carbamazepine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000104	0.000383	CcSEcCtD
Carbamazepine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000104	0.000382	CcSEcCtD
Carbamazepine—Rash—Leflunomide—systemic scleroderma	0.000104	0.000382	CcSEcCtD
Carbamazepine—Dermatitis—Leflunomide—systemic scleroderma	0.000104	0.000382	CcSEcCtD
Carbamazepine—Mental disorder—Prednisone—systemic scleroderma	0.000103	0.000381	CcSEcCtD
Carbamazepine—Nausea—Azathioprine—systemic scleroderma	0.000103	0.000381	CcSEcCtD
Carbamazepine—Headache—Leflunomide—systemic scleroderma	0.000103	0.00038	CcSEcCtD
Carbamazepine—Erythema—Prednisone—systemic scleroderma	0.000103	0.000379	CcSEcCtD
Carbamazepine—Malnutrition—Prednisone—systemic scleroderma	0.000103	0.000379	CcSEcCtD
Carbamazepine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000103	0.000378	CcSEcCtD
Carbamazepine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000376	CcSEcCtD
Carbamazepine—Asthenia—Lisinopril—systemic scleroderma	0.000101	0.000374	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000373	CcSEcCtD
Carbamazepine—Pruritus—Lisinopril—systemic scleroderma	9.99e-05	0.000368	CcSEcCtD
Carbamazepine—Vomiting—Mycophenolic acid—systemic scleroderma	9.97e-05	0.000368	CcSEcCtD
Carbamazepine—Rash—Mycophenolic acid—systemic scleroderma	9.89e-05	0.000364	CcSEcCtD
Carbamazepine—Dermatitis—Mycophenolic acid—systemic scleroderma	9.88e-05	0.000364	CcSEcCtD
Carbamazepine—Hepatitis—Methotrexate—systemic scleroderma	9.87e-05	0.000364	CcSEcCtD
Carbamazepine—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.83e-05	0.000362	CcSEcCtD
Carbamazepine—Headache—Mycophenolic acid—systemic scleroderma	9.83e-05	0.000362	CcSEcCtD
Carbamazepine—Pharyngitis—Methotrexate—systemic scleroderma	9.8e-05	0.000361	CcSEcCtD
Carbamazepine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.78e-05	0.000361	CcSEcCtD
Carbamazepine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.78e-05	0.000361	CcSEcCtD
Carbamazepine—Nausea—Leflunomide—systemic scleroderma	9.77e-05	0.00036	CcSEcCtD
Carbamazepine—Urinary tract disorder—Methotrexate—systemic scleroderma	9.75e-05	0.000359	CcSEcCtD
Carbamazepine—Vision blurred—Prednisone—systemic scleroderma	9.69e-05	0.000357	CcSEcCtD
Carbamazepine—Urethral disorder—Methotrexate—systemic scleroderma	9.67e-05	0.000357	CcSEcCtD
Carbamazepine—Diarrhoea—Lisinopril—systemic scleroderma	9.67e-05	0.000356	CcSEcCtD
Carbamazepine—Anaemia—Prednisone—systemic scleroderma	9.5e-05	0.00035	CcSEcCtD
Carbamazepine—Agitation—Prednisone—systemic scleroderma	9.45e-05	0.000348	CcSEcCtD
Carbamazepine—Angioedema—Prednisone—systemic scleroderma	9.39e-05	0.000346	CcSEcCtD
Carbamazepine—Dizziness—Lisinopril—systemic scleroderma	9.34e-05	0.000344	CcSEcCtD
Carbamazepine—Erythema multiforme—Methotrexate—systemic scleroderma	9.33e-05	0.000344	CcSEcCtD
Carbamazepine—Nausea—Mycophenolic acid—systemic scleroderma	9.32e-05	0.000343	CcSEcCtD
Carbamazepine—Vertigo—Prednisone—systemic scleroderma	9.24e-05	0.00034	CcSEcCtD
Carbamazepine—Eye disorder—Methotrexate—systemic scleroderma	9.22e-05	0.00034	CcSEcCtD
Carbamazepine—Syncope—Prednisone—systemic scleroderma	9.22e-05	0.00034	CcSEcCtD
Carbamazepine—Tinnitus—Methotrexate—systemic scleroderma	9.2e-05	0.000339	CcSEcCtD
Carbamazepine—Cardiac disorder—Methotrexate—systemic scleroderma	9.16e-05	0.000338	CcSEcCtD
Carbamazepine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	9.12e-05	0.000336	CcSEcCtD
Carbamazepine—Loss of consciousness—Prednisone—systemic scleroderma	9.04e-05	0.000333	CcSEcCtD
Carbamazepine—Vomiting—Lisinopril—systemic scleroderma	8.98e-05	0.000331	CcSEcCtD
Carbamazepine—Angiopathy—Methotrexate—systemic scleroderma	8.95e-05	0.00033	CcSEcCtD
Carbamazepine—Immune system disorder—Methotrexate—systemic scleroderma	8.91e-05	0.000329	CcSEcCtD
Carbamazepine—Rash—Lisinopril—systemic scleroderma	8.91e-05	0.000328	CcSEcCtD
Carbamazepine—Convulsion—Prednisone—systemic scleroderma	8.91e-05	0.000328	CcSEcCtD
Carbamazepine—Dermatitis—Lisinopril—systemic scleroderma	8.9e-05	0.000328	CcSEcCtD
Carbamazepine—Mediastinal disorder—Methotrexate—systemic scleroderma	8.89e-05	0.000328	CcSEcCtD
Carbamazepine—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000327	CcSEcCtD
Carbamazepine—Hypertension—Prednisone—systemic scleroderma	8.88e-05	0.000327	CcSEcCtD
Carbamazepine—Chills—Methotrexate—systemic scleroderma	8.86e-05	0.000326	CcSEcCtD
Carbamazepine—Headache—Lisinopril—systemic scleroderma	8.85e-05	0.000326	CcSEcCtD
Carbamazepine—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.76e-05	0.000323	CcSEcCtD
Carbamazepine—Myalgia—Prednisone—systemic scleroderma	8.75e-05	0.000323	CcSEcCtD
Carbamazepine—Arthralgia—Prednisone—systemic scleroderma	8.75e-05	0.000323	CcSEcCtD
Carbamazepine—Anxiety—Prednisone—systemic scleroderma	8.72e-05	0.000321	CcSEcCtD
Carbamazepine—Alopecia—Methotrexate—systemic scleroderma	8.72e-05	0.000321	CcSEcCtD
Carbamazepine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.69e-05	0.00032	CcSEcCtD
Carbamazepine—Mental disorder—Methotrexate—systemic scleroderma	8.65e-05	0.000319	CcSEcCtD
Carbamazepine—Malnutrition—Methotrexate—systemic scleroderma	8.59e-05	0.000317	CcSEcCtD
Carbamazepine—Erythema—Methotrexate—systemic scleroderma	8.59e-05	0.000317	CcSEcCtD
Carbamazepine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.47e-05	0.000312	CcSEcCtD
Carbamazepine—Dysgeusia—Methotrexate—systemic scleroderma	8.41e-05	0.00031	CcSEcCtD
Carbamazepine—Nausea—Lisinopril—systemic scleroderma	8.39e-05	0.000309	CcSEcCtD
Carbamazepine—Anaphylactic shock—Prednisone—systemic scleroderma	8.39e-05	0.000309	CcSEcCtD
Carbamazepine—Oedema—Prednisone—systemic scleroderma	8.39e-05	0.000309	CcSEcCtD
Carbamazepine—Infection—Prednisone—systemic scleroderma	8.34e-05	0.000307	CcSEcCtD
Carbamazepine—Back pain—Methotrexate—systemic scleroderma	8.31e-05	0.000306	CcSEcCtD
Carbamazepine—Shock—Prednisone—systemic scleroderma	8.25e-05	0.000304	CcSEcCtD
Carbamazepine—Nervous system disorder—Prednisone—systemic scleroderma	8.23e-05	0.000303	CcSEcCtD
Carbamazepine—Tachycardia—Prednisone—systemic scleroderma	8.19e-05	0.000302	CcSEcCtD
Carbamazepine—Dizziness—Mycophenolate mofetil—systemic scleroderma	8.18e-05	0.000302	CcSEcCtD
Carbamazepine—Skin disorder—Prednisone—systemic scleroderma	8.15e-05	0.0003	CcSEcCtD
Carbamazepine—Hyperhidrosis—Prednisone—systemic scleroderma	8.11e-05	0.000299	CcSEcCtD
Carbamazepine—Vision blurred—Methotrexate—systemic scleroderma	8.1e-05	0.000298	CcSEcCtD
Carbamazepine—Anorexia—Prednisone—systemic scleroderma	8e-05	0.000295	CcSEcCtD
Carbamazepine—Anaemia—Methotrexate—systemic scleroderma	7.94e-05	0.000293	CcSEcCtD
Carbamazepine—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.87e-05	0.00029	CcSEcCtD
Carbamazepine—Rash—Mycophenolate mofetil—systemic scleroderma	7.8e-05	0.000288	CcSEcCtD
Carbamazepine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.8e-05	0.000287	CcSEcCtD
Carbamazepine—Headache—Mycophenolate mofetil—systemic scleroderma	7.75e-05	0.000286	CcSEcCtD
Carbamazepine—Vertigo—Methotrexate—systemic scleroderma	7.72e-05	0.000284	CcSEcCtD
Carbamazepine—Leukopenia—Methotrexate—systemic scleroderma	7.69e-05	0.000283	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.64e-05	0.000282	CcSEcCtD
Carbamazepine—Insomnia—Prednisone—systemic scleroderma	7.59e-05	0.00028	CcSEcCtD
Carbamazepine—Paraesthesia—Prednisone—systemic scleroderma	7.53e-05	0.000278	CcSEcCtD
Carbamazepine—Convulsion—Methotrexate—systemic scleroderma	7.44e-05	0.000274	CcSEcCtD
Carbamazepine—Dyspepsia—Prednisone—systemic scleroderma	7.39e-05	0.000272	CcSEcCtD
Carbamazepine—Nausea—Mycophenolate mofetil—systemic scleroderma	7.35e-05	0.000271	CcSEcCtD
Carbamazepine—Arthralgia—Methotrexate—systemic scleroderma	7.31e-05	0.00027	CcSEcCtD
Carbamazepine—Myalgia—Methotrexate—systemic scleroderma	7.31e-05	0.00027	CcSEcCtD
Carbamazepine—Chest pain—Methotrexate—systemic scleroderma	7.31e-05	0.00027	CcSEcCtD
Carbamazepine—Decreased appetite—Prednisone—systemic scleroderma	7.29e-05	0.000269	CcSEcCtD
Carbamazepine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.26e-05	0.000268	CcSEcCtD
Carbamazepine—Fatigue—Prednisone—systemic scleroderma	7.23e-05	0.000267	CcSEcCtD
Carbamazepine—Constipation—Prednisone—systemic scleroderma	7.17e-05	0.000264	CcSEcCtD
Carbamazepine—Confusional state—Methotrexate—systemic scleroderma	7.07e-05	0.000261	CcSEcCtD
Carbamazepine—Anaphylactic shock—Methotrexate—systemic scleroderma	7.01e-05	0.000258	CcSEcCtD
Carbamazepine—Infection—Methotrexate—systemic scleroderma	6.97e-05	0.000257	CcSEcCtD
Carbamazepine—Feeling abnormal—Prednisone—systemic scleroderma	6.91e-05	0.000255	CcSEcCtD
Carbamazepine—Nervous system disorder—Methotrexate—systemic scleroderma	6.88e-05	0.000253	CcSEcCtD
Carbamazepine—Thrombocytopenia—Methotrexate—systemic scleroderma	6.87e-05	0.000253	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Prednisone—systemic scleroderma	6.86e-05	0.000253	CcSEcCtD
Carbamazepine—Skin disorder—Methotrexate—systemic scleroderma	6.81e-05	0.000251	CcSEcCtD
Carbamazepine—Hyperhidrosis—Methotrexate—systemic scleroderma	6.78e-05	0.00025	CcSEcCtD
Carbamazepine—Anorexia—Methotrexate—systemic scleroderma	6.68e-05	0.000246	CcSEcCtD
Carbamazepine—Urticaria—Prednisone—systemic scleroderma	6.67e-05	0.000246	CcSEcCtD
Carbamazepine—Abdominal pain—Prednisone—systemic scleroderma	6.63e-05	0.000244	CcSEcCtD
Carbamazepine—Body temperature increased—Prednisone—systemic scleroderma	6.63e-05	0.000244	CcSEcCtD
Carbamazepine—Hypotension—Methotrexate—systemic scleroderma	6.55e-05	0.000241	CcSEcCtD
Carbamazepine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.39e-05	0.000235	CcSEcCtD
Carbamazepine—Insomnia—Methotrexate—systemic scleroderma	6.34e-05	0.000234	CcSEcCtD
Carbamazepine—Paraesthesia—Methotrexate—systemic scleroderma	6.3e-05	0.000232	CcSEcCtD
Carbamazepine—Dyspnoea—Methotrexate—systemic scleroderma	6.25e-05	0.00023	CcSEcCtD
Carbamazepine—Somnolence—Methotrexate—systemic scleroderma	6.23e-05	0.00023	CcSEcCtD
Carbamazepine—Hypersensitivity—Prednisone—systemic scleroderma	6.18e-05	0.000228	CcSEcCtD
Carbamazepine—Dyspepsia—Methotrexate—systemic scleroderma	6.17e-05	0.000227	CcSEcCtD
Carbamazepine—Decreased appetite—Methotrexate—systemic scleroderma	6.1e-05	0.000225	CcSEcCtD
Carbamazepine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.05e-05	0.000223	CcSEcCtD
Carbamazepine—Fatigue—Methotrexate—systemic scleroderma	6.05e-05	0.000223	CcSEcCtD
Carbamazepine—Asthenia—Prednisone—systemic scleroderma	6.02e-05	0.000222	CcSEcCtD
Carbamazepine—Pain—Methotrexate—systemic scleroderma	6e-05	0.000221	CcSEcCtD
Carbamazepine—Pruritus—Prednisone—systemic scleroderma	5.94e-05	0.000219	CcSEcCtD
Carbamazepine—Feeling abnormal—Methotrexate—systemic scleroderma	5.78e-05	0.000213	CcSEcCtD
Carbamazepine—Diarrhoea—Prednisone—systemic scleroderma	5.74e-05	0.000212	CcSEcCtD
Carbamazepine—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.73e-05	0.000211	CcSEcCtD
Carbamazepine—Urticaria—Methotrexate—systemic scleroderma	5.57e-05	0.000205	CcSEcCtD
Carbamazepine—Dizziness—Prednisone—systemic scleroderma	5.55e-05	0.000204	CcSEcCtD
Carbamazepine—Abdominal pain—Methotrexate—systemic scleroderma	5.54e-05	0.000204	CcSEcCtD
Carbamazepine—Body temperature increased—Methotrexate—systemic scleroderma	5.54e-05	0.000204	CcSEcCtD
Carbamazepine—Vomiting—Prednisone—systemic scleroderma	5.33e-05	0.000197	CcSEcCtD
Carbamazepine—Rash—Prednisone—systemic scleroderma	5.29e-05	0.000195	CcSEcCtD
Carbamazepine—Dermatitis—Prednisone—systemic scleroderma	5.29e-05	0.000195	CcSEcCtD
Carbamazepine—Headache—Prednisone—systemic scleroderma	5.26e-05	0.000194	CcSEcCtD
Carbamazepine—Hypersensitivity—Methotrexate—systemic scleroderma	5.17e-05	0.00019	CcSEcCtD
Carbamazepine—Asthenia—Methotrexate—systemic scleroderma	5.03e-05	0.000185	CcSEcCtD
Carbamazepine—Nausea—Prednisone—systemic scleroderma	4.98e-05	0.000184	CcSEcCtD
Carbamazepine—Pruritus—Methotrexate—systemic scleroderma	4.96e-05	0.000183	CcSEcCtD
Carbamazepine—Diarrhoea—Methotrexate—systemic scleroderma	4.8e-05	0.000177	CcSEcCtD
Carbamazepine—Dizziness—Methotrexate—systemic scleroderma	4.64e-05	0.000171	CcSEcCtD
Carbamazepine—Vomiting—Methotrexate—systemic scleroderma	4.46e-05	0.000164	CcSEcCtD
Carbamazepine—Rash—Methotrexate—systemic scleroderma	4.42e-05	0.000163	CcSEcCtD
Carbamazepine—Dermatitis—Methotrexate—systemic scleroderma	4.42e-05	0.000163	CcSEcCtD
Carbamazepine—Headache—Methotrexate—systemic scleroderma	4.39e-05	0.000162	CcSEcCtD
Carbamazepine—Nausea—Methotrexate—systemic scleroderma	4.16e-05	0.000154	CcSEcCtD
